Soluble expression and purification of Bluetongue Virus Type 1 (BTV1) structure protein VP2 in *Escherichia coli* and its immunogenicity in mice

Aiping Wang, Jiajia Yin, Jingming Zhou, Hongfang Ma, Yumei Chen, Hongliang Liu, Yanhua Qi, Chao Liang, Yankai Liu, Jinge Li and Gaiping Zhang

Zhengzhou University, School of Life Sciences, Zhengzhou University, Henan, PR China

**ABSTRACT**

**Background.** The VP2 on the surface of the virus particle is the main structural protein of BTV, which can induce the host to produce neutralizing antibodies and play an important role in the antiviral immunity process. This study aimed to obtain the soluble VP2 and analyze its immunogenicity.

**Methods.** The gene encoding the full-length VP2 of BTV1 was amplified by PCR. The products from restriction enzyme digestion and ligase reaction between VP2 and vector pET-28a were transformed into *E.coli* DH5α. After PCR and sequencing detection, the positive plasmid PET28a-VP2 was transformed into *E.coli* BL21(DE3) and Rosetta(DE3) competent cells, expression induced by IPTG. The fusion protein was expressed in the optimized conditions with the induction of IPTG, purified by affinity chromatography and identified by SDS-PAGE and Western blotting. A total of 5 Balb/c mice aged 6–8 weeks were immunized with the fusion protein at a dose of 30 µg per mouse. Each mouse was immunized three times at an interval of 3 weeks.

**Results.** The recombinant plasmid PET28a-VP2 was successfully constructed. The expression strains were induced by 0.4 mmol/L IPTG at 16 °C for 10 h, and BTV1 VP2 was expressed in a soluble form. The purity of the recombinant VP2 protein (∼109 kDa) was about 90% in the concentration at 0.2 mg/ml after purification. The purified VP2 had good immunoreactivity with BTV1 positive serum. Taken together, this study offered a route for producing soluble BTV VP2, which retains activity and immunogenicity, to be beneficial to the research on developing BTV vaccine, and lay the foundation for further research on BTV.

**INTRODUCTION**

Bluetongue (BT) is a severe noncontagious infectious disease, which is common in sheep and wild ruminants, and occasionally occurs in cattle, camels and carnivores (Sohail et al., 2018). Infected animals often develop symptoms of fever, cyanotic tongue, ulcers in the mouth and stomach and even death (Thiry et al., 2008). The first detailed descriptions of BT in sheep were in 1905, nowadays, BT is listed as a notifiable animal infectious disease.
by OIE and occurs throughout the world causing significant economic losses (Sperlova & Zendulkova, 2011; OIE, 2019).

Bluetongue virus (BTV) is the pathogen of BT and a member of the family Reoviridae, genus Orbivirus (Huismans & Erasmus, 1981). The virus particle has no envelope, icosahedral symmetry about 90 nm in diameter containing a core particle with maximum diameter around 73 nm. Up to now, 27 serotypes of BTV are recognized with no cross-protection between each serotype (Maan Narender et al., 2012). The BTV linear dsRNA genome is approximately 19 kb consisting of 10 segments (Seg 1 to Seg 10) encoding seven structural proteins (VP1-VP7) and four nonstructural proteins (NS1, NS2, NS3/NS3a, NS4). The double capsid structure is formed by four structural proteins, i.e., VP2, VP5, VP3, and VP7. Especially, VP2, encoded by the L2 gene of BTV, is the main structural protein located on the surface of virions (Schwartz-Cornil et al., 2008). Moreover, VP2 is responsible for virus attachment and haemagglutination, inducing neutralizing antibodies and viral serotype determination (Bhattacharya, Noad & Roy, 2007). Hence, the structural protein VP2 with multiple epitopes, good specificity and high sensitivity was selected as a good antigen.

Currently, several genetic engineering BT vaccines including vaccines based on BTV proteins and viral vector vaccines are under development and have an extensive prospect. The serotype-specific immunodominant VP2 protein was selected as the antigen of the BTV protein vaccine. Protein has been studied in bacteria (Xie et al., 2018), in insect cells (Delos et al., 1993; Inumaru & Roy, 1987; Roy, French & Erasmus, 1992; Urakawa et al., 1994), in yeast (Athmaram et al., 2007), and in plants (Fay et al., 2019). Moreover, the prokaryotic expression is most rapid, money-saving and easy to operate, although most of proteins expressed in Prokaryotic system are insoluble and inactive. Mohd Jaafar et al. (2014) successfully expressed two domains (aa 63-471 and 555-956) of BTV4 VP2 in soluble form in bacteria. Li et al. (2016) induced the expression of soluble BTV25 VP2 protein with maltose tag in E.coli. Zhou et al. (2017) obtained three truncated BTV4 VP2 proteins using Prokaryotic expression system. However, no scholars have expressed the full-length BTV1 VP2 in prokaryotic.

Therefore, we decided to express and purify soluble BTV1 VP2 in the Prokaryotic expression system and analyzed its immunogenicity in mice. We expect to lay the foundation for further study on developing potential and safe subunit vaccine for prevention and control BT effectively.

**MATERIALS & METHODS**

**Ethics statement**

Animal experiments were performed in accordance with the guidelines of the Chinese Council on Animal Care. The research protocol was approved by the Animal Care and Use Committee at School of life Sciences, Zhengzhou University.

**Experimental animals**

Ten adult male albino mice, which were chosen to avoid data interference from hormonal variations, were purchased in September 2019 from the Animal Experimental Center.
of Zhengzhou University. The mice were kept in a room maintained at a temperature of 25 ± 2 °C with a 12-h light/dark cycle, and they had free access to food and water. The experimental environment meets the requirements of GB-14925. This study was performed in strict compliance with standard recommendations in the Guide for the Management and Use of Laboratory Animals (published in May 2016). This protocol was approved by the Joint Unit of Zhengzhou University—the Animal Ethics Review Committee of the Key Laboratory of Animal Immunology, Henan Academy of Agricultural Sciences (LLSC100166). In order to avoid the impact of immunogen on the physical and mental health of mice by the experiment, they were sacrificed by cervical dislocation method under xanthazine anesthesia to reduce the pain of the mice.

**Establishment of recombination expression plasmid**

A pair of BTV1 VP2 primers containing EcoRI and XhoI sites were designed according to the complete gene sequence of BTV1 VP2 (GenBank accession number KF664124) and used to amplify the full length VP2 gene (Synthesized by Sangon Biotech, China). The sense primer was 5’-ATGGACGAGCTGGTTAT-3’ and the antisense primer was 5’-TTAAACGTGAGAGCTTTAGT-3’. The PCR amplification was carried out using PrimeSTAR DNA polymerase kits (TaKaRa, China) with the following reaction conditions: a pre-denaturation at 98 °C for 10 sec, 32 cycles of denaturation at 98 °C for 10 s, annealing at 55 °C for 30 s, and extension at 68 °C for 30 s; and an extension at 68 °C for 5 min. The PCR product was visualised in a 1% agarose gel and then purified using DNA Gel Extraction Kit (OMEGA, US). Then, the extracted VP2 gene was inserted between the EcoR I and Xho I sites of the vector pET-28a. The recombinant vector pET-28a-VP2 was identified by restriction enzyme digestion and the BTV1 VP2 insert was verified by sequencing. The recombinant expression vector was confirmed by restriction enzyme digestion and sequencing. E.coli DH5α was used for amplification of the recombinant plasmid. Then, pET28a-VP2 was transformed into E.coli BL21(DE3) and E.coli Rosetta(DE3) competent cell lines to induce the expression of the His-tagged BTV1 VP2 protein.

**Expression and solubility analysis of recombinant protein VP2**

Single colonies of E.coli BL21 (DE3) and E.coli Rosetta (DE3) transformed with the recombinant expression plasmid pET28a-VP2 were respectively inoculated in the tube containing 5 ml of LB medium (containing 50 µg/mL of kanamycin, 50 µg/mL of kanamycin and 34 µg/mL of chloramphenicol) and cultivated overnight at 37 °C in a shaking incubator. Until the OD600 of the culture was about 0.6–0.8, the expression of VP2 was induced by the addition of isopropyl β-D-thiogalactoside (IPTG). After induction, the expression of the fusion protein was analyzed by SDS-PAGE, and the cells were harvested at 25 °C by centrifugation at 10,000 rpm for 15 min. The supernatant was discarded and the cell pellet was washed, frozen, resuspended in phosphate-buffered saline (PBS, pH 7.4), and then disrupted by sonication. The eluted fractions were analyzed by 10% SDS-PAGE. The results of SDS-PAGE were obtained using a Universal Hood III gel imaging system (Biorad, US).
Optimal expression conditions of recombinant protein VP2

The results of the expression of VP2 in the two expression strains were analyzed, VP2 protein in Rosetta (DE3) strain mainly existed in soluble form. Then, the Rosetta (DE3) strain was selected to express the target protein VP2. Moreover, the expression conditions for pET28a-VP2 (Rosseta) containing the temperature, IPTG concentration and time were explored. Recombinant protein VP2 was expressed in a series of inducting temperatures including 16 °C, 25 °C, 30 °C and 37 °C. The fusion protein was induced by a group of IPTG at varied concentrations containing 0.2 mmol/L, 0.4 mmol/L, 0.6 mmol/L, 0.8 mmol/L and 1.0 mmol/L. Afterwards, the optimal expression time was determined according to the arithmetic progression including five values increasing from the beginning value 0 h to the ending value 10 h, using the optimal temperature and IPTG concentration. All results are analyzed using SDS-PAGE.

Purification of recombinant protein VP2

The recombinant protein VP2 was purified by the Ni-NTA agarose (Qiagen, Hilden, Germany). Briefly, the bacterium was resuspended with binding buffer (20 mM of Tris-HCl, 300 mM of NaCl, pH 8.2) and treated by ultrasonic, then, the supernatant was obtained by centrifugation at 12,000 rpm for 10 min. Then the supernatant was added to a pre-equilibrated Ni-chelating affinity chromatography. Then the mixture was incubated at 4 °C at 200 rpm for more than 2 h. After incubation, the wash buffer (20 mM of Tris-HCl, 300 mM of NaCl, 50 mM of imidazole, pH 8.2) was used to remove certain impurities. Then the recombinant protein VP2 attached onto Ni-chelating affinity chromatography was eluted by elution buffer (20 mM of Tris-HCl, 300 mM of NaCl, 100 mM of imidazole, pH 8.2). The purified protein was further analyzed using SDS-PAGE and Western blotting. For Western blotting, a HRP-conjugated 6 × H is was used as the antibody.

Mass spectrometric identification of VP2 protein

It was further confirmed by mass spectrometry that the obtained protein was BTV1 VP2. The specific steps are as follows: The gel band containing the purified protein was carefully excised and transferred into a clean microfuge tube. Then, the sample was sent to biotechnology (Sangon, China) for mass spectrometry.

Reactivity of recombinant protein VP2 with BTV1 positive serum

The reactivity of recombinant protein VP2 with positive serum (BTV1 positive serum obtained from mice immunized with BTV1 inactivated virus) was assayed by western blotting. BTV1 positive serum and HRP-conjugated goat anti-mouse monoclonal antibody were used as primary antibody and secondary antibody, respectively.

Animal tests

For tested serotype, ten Balb/c mice at 6 ~8 weeks old were randomly divided into two groups with five of each. The first group were immunized with recombinant VP2 at a dose of 30 µg/head as the experimental group. In the other group, the animals were not immunized as the control group. The Freund’s complete adjuvant mixed with recombinant VP2 was used in the first injection and the Freund’s incomplete adjuvant was used for the
second and third immunizations. The interval time of immunization was 3 weeks, and blood was collected from the tail vein on 0, 7, 14, 21, 28, 35, 42, 49, 56 days after the first immunization. The serum of immunized mice was collected after centrifugation at 4000 rpm for 10 min.

**Evaluation of the immune effect**

The immune effect of fusion protein VP2 was analyzed by dot-ELISA and indirect ELISA assay. The nitrocellulose filter membrane was coated by recombinant protein VP2 and inactivated BTV. The 200-fold diluted positive serum and 1000-fold diluted HRP-conjugated goat anti-mouse IgG antibody (Proteintech, US) were used as the primary antibody and the secondary antibody, respectively. The microplate was coated with 50 µl purified recombinant protein VP2 (0.05 mg/well) and primary antibodies was a series of gradient diluted serum beginning with 100-fold serum as well as the secondary antibody was HRP-conjugated goat anti-mouse IgG antibody. Moreover, the microplate was coated with 50 µl purified recombinant protein VP2 (0.05 mg/well) and a series of serum collected from the first week to the eighth week after immunization, as well as the secondary antibody was HRP-conjugated goat anti-mouse IgG antibody. The result of indirect ELISA was read using a Microplate Reader (BioTek Instruments, Inc, Winooski, VT, US) at 490 nm.

**RESULT**

**Prokaryotic expression vector construction**

Construction of the recombinant plasmid was in accordance with the principles of plasmid restructuring (Fig. 1). The prokaryotic expression vector pET28a-VP2 was successfully constructed by amplification of the target gene, restriction enzyme digestion, transforming into competent cells, coating plates, selecting monoclonal colony. The results of PCR detection showed that some monoclonal colonies had specific band was about 3000 bp in 1% agarose gel electrophoresis (Fig. 2A), which was accordant to the theoretical length of VP2 gene. The recombinant plasmid was digested by the restriction enzymes EcoRI and XhoI. Agarose gel electrophoresis of the digest revealed a DNA band at about 3000 bp (Fig. 2B). The inserted fragment was verified by sequencing, which was identical to the published BTV1 VP2 gene sequence.

**Expression and solubility identification of recombinant protein VP2**

The pET28a-VP2 transformed into the strain BL21(DE3) and Rosetta(DE3) were induced by IPTG to express VP2. The results of SDS-PAGE and western blotting showed that the recombinant protein VP2 induced by IPTG was expressed (≈109 kDa) in both BL21(DE3) (Figs. 3A and 3B) and Rosetta (DE3) (Figs. 3D and 3E) strain. The size was consistent with the expected size. The solubility analysis of recombinant protein VP2 by SDS-PAGE showed that the supernatant expression of VP2 in Rosetta (DE3) was higher (Figs. 3C and 3F).

**Optimization of recombinant protein VP2 expression conditions**

The expression conditions of recombinant protein VP2 were optimized in inducing temperatures, inducing times, and IPTG concentrations. As shown in Fig. 4, fusion protein
Figure 1  Schematic diagram of the constructed recombinant plasmid. (A) A history of construction to recombine expression plasmid pET28a-VP2, (B) the sites and sequences of restriction enzyme XhoI and EcoRI.

Full-size DOI: 10.7717/peerj.10543/fig-1

Figure 2  PCR detection and restriction enzyme digestion. (A) PCR result of bacterial liquid. Lane 1, marker. Lanes 2–7 denote selected 6 monoclonal colonies, clones 2–6 have specific bands at about 3,000 bp. (B) The recombinant expression vector pET-28a-VP2 digestion with restriction enzymes EcoRI and XhoI. Lane 1, marker. Lane 2 denotes pET-28a-VP2 plasmid and lane 3 denotes products of pET-28a-VP2 by restriction enzyme digestion.

Full-size DOI: 10.7717/peerj.10543/fig-2
attains its maximum expression quantity when induced by 0.8 mM IPTG at 16 °C for 10 h. The previous study has shown that excessively high IPTG concentrations will inhibit the growth of bacteria (Donovan, Robinson & Glick, 1996), so 0.4 mM IPTG was finally selected as the induced concentration.

**Purification of recombinant protein VP2**

The recombinant protein VP2 was purified using Ni-chelating affinity chromatography. The purity of the target protein was above 90% explained by SDS-PAGE gel scan analysis.
Figure 4  SDS-PAGE analysis of the optimal expression conditions of recombinant VP2 protein.
Marker denotes the middle-ranged protein marker. (A) The optimization of inducing temperature. When the recombination strain was induced for 18 h by 0.5 mM IPTG at 16 °C, 25 °C, 30 °C, 20 µL of the culture supernatant was collected. The culture supernatant mixed with the 5 × loading buffer were boiled and then determined by SDS-PAGE. (B) The optimization of inducing time. When the recombination strain was induced by 0.5 mM IPTG at 16 °C from the beginning value 0 h to the ending value 10 h, 20 µL of the culture supernatant was collected and determined by SDS-PAGE. (C) and (D) The optimization of IPTG concentration. The fusion protein was induced for 18 h by a range of concentrations of IPTG containing 0.2 mmol/L, 0.4 mmol/L, 0.6 mmol/L, 0.8 mmol/L and 1.0 mmol/L for 18 h at 16 °C. The culture supernatant (D) was determined by SDS-PAGE. Then the induced cells were cracked by ultrasonic, the lysate supernatant and the lysate pellet (C) were analyzed by SDS-PAGE.

FIGURE 4

Figure 5A and western blotting (Fig. 5B). The concentration of VP2 was 0.2 g/mL determined by Bradford Protein Assay Kit and a total f 60 mg recombinant protein VP2 was obtained from 300 ml bacterial liquid.

Mass spectrometric identification of VP2 protein

The mass spectrometry identification result table (Fig. 6A), and one of the mass spectra of trypsin digestion in the gel band (Fig. 6B) showed that the peptide fragments of the protein we purified have a high degree of match with the VP2 protein sequence in the protein database. The results above indubitably determined the identity of the recombinant His-tagged VP2 protein.

Reactivity of recombinant protein VP2 with BTV1 positive serum

The result of western blotting showed that VP2 had a high reactivity with BTV1 positive serum (Fig. 7).

Evaluation of immunization effect

The results of dot-ELISA showed that the serum of mice immunized with recombinant protein VP2 could specifically react with BTV1 inactivated virus, while the serum of mice in the control group had no response (Fig. 8A). The serum titer of VP2 when used as
coating protein was up to $1: 2.048 \times 10^5$ (Fig. 8B), and anti-VP2 antibody titer increased with immunization time (Fig. 8C).

**DISCUSSION**

Bluetongue virus causes a severe infectious disease BT. BTV has many serotypes and there is no cross-protection among different serotypes. It is difficult to control and eliminate BT using conventional methods due to its asymptomatic infection. Vaccination is a very effective way to control BT outbreaks (Baetza, 2014). However, the existing modified live vaccines and inactivated vaccines have some disadvantages. The modified live vaccine is high cost and its toxic residual may cripple ruminants (Savini et al., 2014; Savini et al., 2007). The inactivated vaccines need to immunize animals several times (González et al., 2010). Moreover, the nonreplicative vaccine is expensive and less effective and there are some problems in terms of safety and market acceptance for effective and cheap replication-vaccine (Feenstra & Van Rijn, 2016). All these efforts have been made with VLPs expressed in the baculovirus system for more than 20 years. Although VLPs vaccines have been achieved very promising results in large animal experiments, they have not yet been marketed (Stewart et al., 2010). The precise reason for current status has not yet been
described in the literature, it may because that the production method is not cost-effective. Therefore, subunit vaccines will be a good choice to address these issues.

BTV structural protein VP2 can induce a protective immune response in sheep (Nunes et al., 2014). Moreover, it is not feasible to obtain protein VP2 using large-scale chemical purification (Huismans, Walt & Erasmus, 1985). It was reported that VP2 was expressed in the baculovirus expression system (Delos et al., 1993; Inumaru & Roy, 1987; Roy, French & Erasmus, 1992; Urakawa et al., 1994); two domains of VP2 were successfully expressed in the prokaryotic system (Mohd Jaafar et al., 2014), but the full-length recombinant protein of BTV1 VP2 was not expressed in prokaryotic expression system. The prokaryotic expression system is a mature expression system, which has the advantages of simple operation, easy purification, and mass production (Zhang et al., 2015). In this study, it is the first time to express the full-length BTV1 VP2 using the prokaryotic expression system. The recombinant BTV1 VP2 with good solubility reacts with BTV1 positive serum from mouse, and the immunization analysis showed that serum of mice immunized with VP2 displayed specific reactivity with BTV1 inactivated virus. In addition, the immunized mice produced high-potency specific antibodies against VP2 protein. Sera from Balb/c mice immunised with the soluble recombinant VP2D1 of BTV-4, neutralised the homologous virus, while significantly lower NAb titres were observed with sera of mice immunised with soluble VP2D2 (Mohd Jaafar et al., 2014). These indicated that the recombinant protein VP2 we obtained has good Immunoreactivity.

Futhermore, the study also found that the reactivity of VP2 to BTV1 positive serum from mouse was weaker than that of VP7. It may be caused by the following reasons: VP2 is located in the outermost layer of the virion, which makes VP2 have highly hydrophilic and
Western blotting to identify the immunoreactivity of recombinant protein VP2. Marker denotes the middle-ranged protein marker. Western blotting analysis of the VP2 protein by BTV1 positive serum demonstrated that a specific reaction band was ∼109 kDa in lane 2.

contains serotype-specific epitopes that may be recognized by neutralized hemagglutination inhibitor (HI) antibodies (Zhang et al., 2010); Amino acid sequence of VP2 is highly variable resulting in mutations amino acid cause the conformation changes of the VP2 protein and the spatial position changes of epitopes (Maan Narender et al., 2012); Another reason is that VP7 located on the outer surface of the core particles and contains BTV group-specific epitopes, which can stimulate the body to produce a strong group-specific immune response (Hosamani et al., 2011; Anthony et al., 2007).
CONCLUSIONS

In this study, the recombinant vector pET28a-VP2 was successfully constructed, and the soluble recombinant VP2 was successfully obtained using the prokaryotic expression system. After optimizing the purification conditions, the target protein with high purity was finally obtained, which could specifically react with BTV1 positive serum. The recombinant VP2 was used to immunize Balb/c mice and the serum titer of indirect ELISA was $1: 2.048 \times 10^5$. Dot-ELISA results showed that the serum of mice immunized with VP2 could react specifically with BTV1 inactivated virus.

In short, the recombinant protein BTV1 VP2 in the full-length sequence has been expressed for the first time in the Prokaryotic expression system. It does not only lay the
foundation for the study of the structure and function of BTV1 VP2 but also the production of subunit vaccines provides a better theoretical proof.

ACKNOWLEDGEMENTS
We are grateful to Yunnan Academy of Animal Husbandry and Veterinary Sciences for the gift of inactivated BTV. We thank Dr. Rui Jia for revising the grammatical errors and reorganizing this manuscript. We thank Miss Jinran Du for assisting us in our experiments.

ADDITIONAL INFORMATION AND DECLARATIONS

Funding
This work was supported by the Research and development of prevention and control technology for severe foreign animal diseases (2017YFD0502300), Development of a new genetic engineering vaccine for bluetongue disease and a kit for the identification of natural infections and vaccine immunity (2017YFD0502304) and Development of a new genetically engineered subunit vaccine for bluetongue virus (2017YFD0502304-4). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.

Grant Disclosures
The following grant information was disclosed by the authors:
The Research and development of prevention and control technology for severe foreign animal diseases: 2017YFD0502300.
Development of a new genetic engineering vaccine for bluetongue disease and a kit for the identification of natural infections and vaccine immunity: 2017YFD0502304.
Development of a new genetically engineered subunit vaccine for bluetongue virus: 2017YFD0502304-4.

Competing Interests
The authors declare there are no competing interests.

Author Contributions
• Aiping Wang conceived and designed the experiments, authored or reviewed drafts of the paper, and approved the final draft.
• Jiajia Yin conceived and designed the experiments, performed the experiments, analyzed the data, prepared figures and/or tables, and approved the final draft.
• Jingming Zhou and Chao Liang analyzed the data, prepared figures and/or tables, and approved the final draft.
• Hongfang Ma performed the experiments, analyzed the data, prepared figures and/or tables, and approved the final draft.
• Yumei Chen conceived and designed the experiments, performed the experiments, authored or reviewed drafts of the paper, and approved the final draft.
• Hongliang Liu, Yanhua Qi and Yankai Liu analyzed the data, authored or reviewed drafts of the paper, and approved the final draft.
Jinge Li and Gaiping Zhang performed the experiments, authored or reviewed drafts of the paper, and approved the final draft.

**Animal Ethics**
The following information was supplied relating to ethical approvals (i.e., approving body and any reference numbers):
Zhengzhou University Life Science Ethics Review Committee approved this study.

**Data Availability**
The following information was supplied regarding data availability:
The raw measurements are available in the Supplemental Files.

**Supplemental Information**
Supplemental information for this article can be found online at http://dx.doi.org/10.7717/peerj.10543#supplemental-information.

**REFERENCES**

Anthony S, Jones H, Darpel KE, Elliott H, Maan S, Samuel A, Mellor PS, Mertens PPC. 2007. A duplex RT-PCR assay for detection of genome segment 7 (VP7 gene) from 24 BTV serotypes. *Journal of Virological Methods* 141(2):188–197 DOI 10.1016/j.jviromet.2006.12.013.

Athmaram TN, Bali G, Kahng GG, Dwarakanath S. 2007. Heterologous expression of bluetongue vp2 viral protein fragment in pichia pastoris. *Virus Genes* 5(2):265–271 DOI 10.1007/s11262-006-0061-0.

Baetza HJ. 2014. Eradication of bluetongue disease in Germany by vaccination. *Veterinary Immunology and Immunopathology* 158:116–119 DOI 10.1016/j.vetimm.2013.09.001.

Bhattacharya B, Noad RJ, Roy P. 2007. Interaction between bluetongue virus outer capsid protein VP2 and vimentin is necessary for virus egress. *Virology Journal* 4:7 DOI 10.1186/1743-422X-4-7.

Delos SE, Montross L, Moreland BR, Garcea RL. 1993. Expression of the polyomavirus VP2 and VP3 proteins in insect cells: coexpression with the major capsid protein vp1 alters VP2/VP3 subcellular localization. *Virology* 194(1):393–398 DOI 10.1006/viro.1993.1274.

Donovan RS, Robinson CW, Glick BR. 1996. Review: optimizing inducer and culture conditions for expression of foreign proteins under the control of the lac promoter. *Journal of Industrial Microbiology* 16(3):145–154 DOI 10.1007/BF01569997.

Fay PC, Attoui H, Batten C, Jaafer FM, Lomonossoff GP, Daly JM, Mertens PPC. 2019. *Nicotiana benthamiana* raises neutralising antibodies and a protective immune response in IFNAR−/− mice. *Vaccine* 2:100026 DOI 10.1016/j.jvacx.2019.100026.

Feenstra F, Van Rijn PA. 2016. Current and next-generation bluetongue vaccines: requirements, strategies, and prospects for different field situations. *Critical Reviews in Microbiology* 43(2):142–155 DOI 10.1080/1040841X.2016.1186005.
González JM, Figueras L, Ortega ME, Lozano M, de Arcaute Ruiz M, Royo R, Cebrián LM, Ferrer LM, Fariñas F, de Jalón García JA, De las Heras M. 2010. Possible adverse reactions in sheep after vaccination with inactivated BTV vaccines. *Veterinary Record* 166(24):757–758 DOI 10.1136/vr.b4849.

Hosamani M, Shimizu S, Hirota J, Kokuho T, Kubota T, Watanabe S, Ohta M, Muneta Y, Inumaru S. 2011. Expression and characterization of bluetongue virus serotype 21 VP7 antigen: C-terminal truncated protein has significantly reduced antigenicity. *Journal of Veterinary Medical Science* 73(5):609–613 DOI 10.1292/jvms.10-0213.

Huismans H, Erasmus BJ. 1981. Identification of the serotype-specific and group-specific antigens of bluetongue virus. *Onderstepoort Journal of Veterinary Research* 48(2):51–58 DOI 10.1080/00480169.1981.34856.

Huismans H, Walt NTVD, Erasmus BJ. 1985. Immune response against the purified serotype specific antigen of bluetongue virus and initial attempts to clone the gene that codes for the synthesis of this protein. *Progress in Clinical and Biological Research* 178:347–353.

Inumaru S, Roy P. 1987. Production and characterization of the neutralization antigen VP2 of bluetongue virus serotype 10 using a baculovirus expression vector. *Virology* 157:472–479 DOI 10.1016/0042-6822(87)90289-3.

Li Y, Li X, Wu X, Zang M, Xie S, Jiang Y. 2016. Prokaryotic expression of VP2 protein of Bluetongue disease virus serotype 25 and preparation of monoclonal antibody. *Journal of Northeast Agricultural University* 47(12):65–73 DOI 10.19720/j.cnki.issn.1005-9369.2016.12.009.

Maan Narender S, Sushila M, Belaganahalli Manjunatha N, Ostlund Eileen N, Johnson Donna J, Kyriaki N, Mertens Peter PC. 2012. Identification and differentiation of the twenty six bluetongue virus serotypes by RT-PCR amplification of the serotype-specific genome segment 2. *PLOS ONE* 7(2):e32601 DOI 10.1371/journal.pone.0032601.

Mohd Jaafar F, Belhouchet M, Vitour D, Adam M, Breard E, Zientara S, Mertens PPC, Attoui H. 2014. Immunisation with bacterial expressed VP2 and VP5 of bluetongue virus (BTV) protect α/β interferon-receptor knock-out (IFNAR-/-) mice from homologous lethal challenge. *Vaccine* 32(A2032):4059–4067 DOI 10.1016/j.vaccine.2014.05.056.

Nunes SF, Hamers C, Ratinier M, Shaw A, Brunet S, Hudelet Pl, Palmarini M. 2014. A synthetic biology approach for a vaccine platform against known and newly emerging serotypes of bluetongue virus. *Journal of Virology* 88(21):12222–12232 DOI 10.1128/JVI.02183-14.

Roy P, French TJ, Erasmus BJ. 1992. Protective efficacy of viruslike particles for bluetongue disease. *Vaccine* 10:28–32 DOI 10.1016/0264-410X(92)90415-G.

Savini G, Lorusso A, Paladini C, Migliaccio P, Di Gennaro A, Di Provvido A, Scacchia M, Monaco F. 2014. Bluetongue serotype 2 and 9 modified live vaccine viruses as causative agents of abortion in livestock: a retrospective analysis in Italy. *Transboundary and Emerging Diseases* 61(1):69–74 DOI 10.1111/tbed.12004.
Savini G, Ronchi GF, Leone A, Ciarelli A, Migliaccio P, Franchi P, Mercante MT, Pini A. 2007. An inactivated vaccine for the control of bluetongue virus serotype 16 infection in sheep in Italy. *Veterinary Microbiology* 124(1–2):140–146 DOI 10.1016/j.vetmic.2007.04.017.

Schwartz-Cornil I, Mertens PPC, Contreras V, Hemati B, Zientara S. 2008. Bluetoongue virus: virology, pathogenesis and immunity. *Veterinary Research* 39(5):46 DOI 10.1051/vetres:2008023.

Sohail T, Yaqub T, Shafee M, Abbas T, Nazir J, Ullah N, Rabbani M, Chaudhary MH, Mukhtar N, Habib M, Rahman AU, Malik AI, Ghafoor A, Zahoor MY, Shabbir MZ. 2018. Seroprevalence of Bluetongue Virus in small ruminants in Balochistan province, Pakistan. *Transboundary and Emerging Diseases* 65(5):1272–1281 DOI 10.1111/tbed.12871.

Sperlova A, Zendulkova D. 2011. Bluetoongue: a review. *Veterinární Medicína* 56(9):430–452 DOI 10.1051/vetres:2008023.

Stewart M, Bhatia Y, Athmaran TN, Noad R, Gastaldi C, Dubois E, Russo P, Thiéry R, Sailléau C, Brédard E, Zientara S, Roy P. 2010. Validation of a novel approach for the rapid production of immunogenic virus-like particles for bluetongue virus. *Vaccine* 28(17):0–3054 DOI 10.1016/j.vaccine.2009.10.072.

Thiry, Etienne, Zimmer, JeanYves, Haubruge, Eric. 2008. Bluetoongue: virology, pathogenesis and biology of the culicoide vector. *Parasit Vectors* 29:11(1) DOI 10.1186/s13071-018-3182-0.

Urakawa T, French TJ, Adachi Y, Fukusho A, LeBlois H, Flamand M, Mertens P, Roy P. 1994. Synthesis of recombinant baculoviruses expressing the outer capsid protein VP2 of five BTV serotypes and the induction of neutralizing antibodies to homologous and heterologous BTV serotypes. *Virus Research* 31(2):149–161 DOI 10.1016/0168-1702(94)90001-9.

**World Organisation for Animal Health (OIE). 2019. Notifiable diseases list.** Paris: World Organisation for Animal Health.

Xie S, Shi Y, Gong R, Cui W, Jiang Y, Liu M, Wang L, Zhou H, Qiao X, Li Y, Xu Y, Tang L. 2018. Identification of antigenic epitopes of monoclonal antibodies against the vp2 protein of the 25 serotype of bluetongue virus. *Veterinary Microbiology* S0378113518300737 DOI 10.1016/j.vetmic.2018.04.008.

Zhang X, Boyce M, Bhattacharya B, Zhang X, Schein S, Roy P, Zhou ZH. 2010. Bluetoongue virus coat protein VP2 contains sialic acid-binding domains, and VP5 resembles enveloped virus fusion proteins. *Proceedings of the National Academy of Sciences of the United States of America* 107(14):6292–6297 DOI 10.1073/pnas.0913403107.

Zhang J, Liu X, Huang N, Hu Z, Li Z. 2015. Soluble expression and purification of the functional interleukin-30 protein in escherichia coli. *Preparative Biochemistry & Biotechnology* 46(6):539–545 DOI 10.1080/10826068.2015.1045608.

Zhou H, Li J, Xie S, Zang M, Xu Y, Qiao X, Wang L, Jiang Y, Cui W, Li Y, Tang L. 2017. Expression and purification of the outer shell protein vp2 of the 4th serotype bluetongue virus, and preparation of monoclonal antibodies against this protein. *Process Biochemistry* 61(oct):119–123 DOI 10.1016/j.procbio.2017.06.027.